EGFR and glioblastoma: While activating mutations in RAS proteins are rarely found in the clinic, loss of the negative regulator NF1 is common, as well as amplifications and/or activating mutations in various RAS pathway proteins including epidermal growth factors receptor (EGFR), which are found in >50% of glioblastomas (Brennan et al., 2013; Hoogstrate et al., 2022; McLendon et al., 2008).